To clarify about the status of these drugs:
On 12/23, HHS announced it would PAUSE distribution of some (bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV) of the monoclonal treatments, bc they were predicted to be INEFFECTIVE against Omicron (IOW, great for Delta... waste of a scarce & expensive resource for Omicron). This did not apply to sotrovimab which did not have data indicating lack of effectiveness and was never stopped (tho supply IS limited). Indeed, as to sotrovamab, HHS said on 12/23: "Shipments of sotrovimab did resume this week, and delivery of 55,000 doses of product has begun. An additional 300,000 doses of sotrovimab will be available for distribution in January."
The same day (12/23) the FDC granted emergency use authorization (EUA) for the Merck pill treatment (EUA was given to Pfizer the day before, on 12/22). Now, IIRC, tho the Merck pill got EUA, its studies did not show it being very effective - at least not as effective as Pfizer's pill. I believe Merck was only like 30% effective against hospitalization/death vs placebo and didn't do ANYTHING for those who have antibodies from a prior Covid infection (or from those who are vaccinated). As to the Pfizer pill (Paxlovid), that one seems to work better at preventing hospitalization/death (like 90%), even from Omicron. NIH has said the Pfizer pill can have "significant and complex" interactions with other drugs, including OTC supplements (so I gotta wonder if all of us taking, say, zinc, in an effort to help avoid infection, may end up SOL if they get it and can't take the pfizer pill until the zinc is out of our system - zinc may not be such a big deal, but there are other drugs that take days to get cleaned out). In any event, I don't think anyone can expect the pills to magically appear & be distributed nationwide in the 2 weeks since it received EUA (tho if I had the ability to snap my fingers and have millions of doses of anything mass produced w/in 10-15 days, I'd be heading for retirement right about now )
On 12/29/21, HHC clarified that the pause of SOME monoclonal treatments was ONLY in states where Omicron was the dominant (greater than 80%) strain. The announcement noted that: The purpose of this pause is to ensure effective product is available in most sites. In regions that have less than 80% prevalence of the Omicron variant, states and territories will continue to receive allocations of the two products to use as clinically appropriate.
On 12/30, the NIH's treatment guidelines panel issued guidance on all of these post-infection drugs (including the Pfizer & Merck pills that received EUA the prior week). That guidance included adding Remdesiver for treating covid patients (but that one is administered via a 3-day IV, while Sotrovimab is a single IV infusion - so it is logistically OK for HOSPITALIZED patients, but using it on an OUTPATIENT basis is unwieldly and "off label", tho Drs use drugs in "off label" ways all the time). It also clarified that if Delta is still the dominant strain, the other treatments MAY be given, "with the understanding that this treatment would be ineffective if they are infected with the Omicron"
Then on 12/31, HHS announced that in light of the NIH's guidelines & the "significant variability" in the presence of Omicron, "all states and territories can continue to order both Lilly (bamlanivimab plus etesevimab) and Regeneron (casirivimab plus imdevimab) monoclonal antibody products from HHS based on allocated amounts for clinically appropriate use"
So - basically SOME of the drugs were paused for one week while the scientists could get a handle on how they would/should/could be used effectively when delta & omicron seem to be battling it out for dominance (I could be wrong, but I assume folks are still getting other strains, but in MUCH smaller numbers)
Also, it may be helpful for those concerned about vaccine reactions to look up what the NIH and CDC and manufacturer's have to say about all of these drugs. There is still potential not only for ineffectiveness, but more importantly for serious, and life changing side effects - tho I do not know if the risks of adverse reaction from the post-infection drugs are less/more/same as the potential for adverse reaction from the vaccine(s).